Pfizer in revised deal on glaucoma implant drug worth up to $168M for pSivida
This article was originally published in Scrip
Executive Summary
Drug delivery specialist pSivida is gaining a $2.3 million payment from Pfizer as it prepares to advance forward with a Phase I/II trial of a bioerodible eye implant designed to deliver long-term, sustained release latanoprost, a marketed product for glaucoma and ocular hypertension.